6 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 8 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 5, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Eccogene: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine ECC0509, Metformin, Caffeine - Steatohepatitis, Nonalcoholic, Osteo Arthritis | Phase 1 | Not yet recruiting | Eccogene | 40 | 2026-11-01 | 2026-10-14 |
| Study of ECC4703 With Sulfasalazine and Pitavastatin ECC4703, Sulfasalazine, Pitavastatin - Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia | Phase 1 | Recruiting | Eccogene | 40 | 2026-08-07 | 2026-09-10 |
| MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial ECC4703, Placebo, Semaglutide - Adult Obesity, Weight Management | Phase 2 | Active not recruiting | Eccogene | 151 | 2026-03-23 | 2026-06-25 |
| ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants ECC4703 F0 formulation, ECC4703 F1 formulation, ECC4703 F2 formulation - Metabolic Dysfunction-Associated Steatohepatitis | Phase 1 | Recruiting | Eccogene | 72 | 2026-01-07 | 2026-09-10 |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) Placebo, ECC4703, ECC0509 - Metabolic Dysfunction-associated Steatohepatitis | Phase 2 | Recruiting | Eccogene | 160 | 2025-12-15 | 2026-10-09 |
| A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus AZD5004, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 1 | Completed | Eccogene | 45 | 2025-06-17 | 2025-12-23 |
| ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants ECC5004, Midazolam, Rosuvastatin - Type 2 Diabetes Mellitus | Phase 1 | Completed | Eccogene | 48 | 2024-02-08 | 2024-07-22 |
| ECC5004 RBA FE Study in Healthy Participants ECC5004 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Eccogene | 14 | 2024-02-06 | 2024-07-17 |
| FTIH of ECC5004 in Healthy and Diabetic Participants Placebo, ECC5004 - Type 2 Diabetes Mellitus | Phase 1 | Completed | Eccogene | 69 | 2022-12-01 | 2024-07-17 |
| FTIH of ECC4703 in Healthy Volunteers ECC4703, Placebo - Non-alcoholic Steatohepatitis (NASH) | Early Phase 1 | Completed | Eccogene | 75 | 2022-08-16 | 2024-07-05 |
| FTIH Study of ECC0509 in Healthy Volunteers Placebo, ECC0509 - Nonalcoholic Steatohepatitis, Osteoarthritis | Phase 1 | Completed | Eccogene | 89 | 2021-07-26 | 2024-09-25 |
Non-alcoholic Fatty Liver Disease (5) · Diabetes Mellitus, Type 2 (4) · Obesity (2) · Dyslipidemias (1) · Liver Diseases (1) · Osteoarthritis (1) · Overweight (1)
Midazolam (2) · Atorvastatin (1) · Caffeine (1) · Digoxin (1) · Metformin (1) · Rosuvastatin Calcium (1) · Sulfasalazine (1) · pitavastatin (1) · semaglutide (1)
United States (6) · Australia (4) · China (1)